Although technical advances enable normal epicardial coronary artery blood flow to be restored in most patients suffering myocardial infarction, restoration of blood flow is not always followed by improved myocardial perfusion. Recently, therefore, interest in the assessment of myocardial perfusion has grown, and a number of different assessment methods are available. The aim of this article was to provide an evaluation of the additional information that can be obtained from the widely used technique of conventional coronary angiography. We present a review of the data on epicardial coronary artery blood flow (both semiquantitative and quantitative) and on microvascular blood flow that can be obtained using coronary angiography and discuss their prognostic significance.

**Key words:** Coronary angiography. Coronary blood flow. Myocardial perfusion.

---

**INTRODUCTION**

The main aim in treating acute myocardial infarction (AMI) is to restore patency in the epicardial coronary artery. The theory of the “open artery” is based on two fundamental factors: time (as soon as possible) and size (as much flow as possible). Whatever the reperfusion method used, as demonstrated in many studies, the final aim is that the angiographic parameter, epicardial blood flow, is normal. Given that the latest developments make it possible to restore “normal” epicardial flow in more than 90% of the patients and that, given this is achieved, a significant number of patients still have unresolved ST segment and their myocardial perfusion is not restored under myocardial contrast echocardiography (MCE), interest has shifted from the epicardial arteries towards myocardial perfusion. There are several methods to assess the state of coronary microcirculation and myocardial perfusion, from the simplest—analyzing a previously resolved ST-segment elevation in the electrocardiogram (ECG), to the more complex—positron emission tomography (PET). The aim of this article is to review the findings obtained with coronary angiography to assess the quality of both epicardial and microvascular reperfusion.

**Coronary Angiography: Beyond Coronary Anatomy**

Aunque los avances tecnológicos permiten restaurar el flujo coronario normal en la arteria epicárdica en la mayoría de los pacientes con infarto de miocardio, no en todos los casos se traduce en la mejora de la perfusión miocárdica; por ello, el interés clínico en la evaluación de ésta ha crecido recientemente. Son varios los métodos que permiten valorar este parámetro, pero el objetivo de esta revisión es analizar la información adicional que ofrece una técnica ampliamente usada, la simple coronariografía. Se revisan los datos de flujo epicárdico (tanto de forma semicuantitativa como cuantitativa) y microvascular que se pueden obtener con la coronariografía y su implicación pronóstica.

**Palabras clave:** Angiografía coronaria. Flujo coronario. Perfusión miocárdica.

---

**RELEVANCE AND LIMITATIONS OF ASSESSING EPICARDIAL FLOW**

**Open Epicardial Artery: TIMI Flow Grading**

The evaluation of blood flow in the epicardial coronary artery was formalized 20 years ago by the TIMI research group (Thrombolysis In Myocardial Infarction) with the so-called TIMI flow grades. Table 1 shows the characteristics of each grade. Many studies have demonstrated the correlation between this parameter and later events such as:
reinfarction,\textsuperscript{30-32} mortality,\textsuperscript{2,4,33,34} free wall rupture,\textsuperscript{35} development of ventricular aneurysm,\textsuperscript{36} or the appearance of arrhythmias.\textsuperscript{37-40} This correlation with prognosis, which was initially described for thrombolytic treatment in acute myocardial infarction (AMI), has also been extended to percutaneous coronary intervention therapy (PCI).\textsuperscript{39-44} This relationship has been shown to be so strong that TIMI 3 flow is normally used as a parameter to evaluate the efficacy of different treatments instead of the relevant clinical events.\textsuperscript{43-52}

This classification allows us to establish the superiority of TIMI 3 flow over other parameters, even over TIMI grade 2-2 meta-analyses\textsuperscript{33,34} report that early mortality was significantly lower among patients with TIMI 3 flow at 90 min after fibrinolysis than in the group with TIMI 2 flow (3.7\% vs 6.6\%; odds ratio [OR] 0.55; 95\% confidence interval [CI], 0.4-0.76) or than in group with TIMI 0 or TIMI 1 flows (9.2\%; OR=0.38; 95\% CI, 0.29-0.5). With the development of repatency therapy using PCI, the use of these predictors has continued to prove their validity,\textsuperscript{11} although some studies point out that the difference in mortality between TIMI 2 and 3 grades might not be so marked nowadays with the use of invasive therapies that combine fibrinolytic drugs and PCI.\textsuperscript{23} On the other hand, technical developments in the intervention field (e.g. stenting,\textsuperscript{53,54} thrombectomy devices,\textsuperscript{55,56} distal protection systems\textsuperscript{57-60}) have not been associated universally with an improvement in TIMI flow.

Nevertheless, this grading system has some limitations:

1. The most relevant limitation is its subjectivity, which leads to important discrepancies,\textsuperscript{61} even when

### TABLE 1. Epicardial Flow and Myocardial Perfusion Grading Systems

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epicardial blood flow: TIMI flow grades (TFG)</strong></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Absence of antegrade flow after the occlusion point</td>
</tr>
<tr>
<td>1</td>
<td>The contrast agent passes through the occluded area, without opacifying the entire length of the artery by the end of the injection</td>
</tr>
<tr>
<td>2</td>
<td>The contrast agent opacifies the entire artery, but is remarkably slower in the non-culprit arteries or in the area proximal to the occluded section of the artery. A later subclassification distinguishes between grade 2a (slow filling, within 5 heart beats), grade 2b (slow filling in more than 5 heart beats) and grade 2c (normal filling, slow washout)</td>
</tr>
<tr>
<td>3</td>
<td>Normal antegrade flow and contrast clearance, similar to those in non-culprit arteries or proximal to the occluded section of the artery</td>
</tr>
<tr>
<td>4</td>
<td>Antegrade flow and clearance of contrast is faster than in non-culprit arteries</td>
</tr>
<tr>
<td><strong>Microvascular flow: TIMI myocardial perfusion grades (TMPG)</strong></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Absence or minimum blush of the myocardium in the distribution section of the culprit artery</td>
</tr>
<tr>
<td>1</td>
<td>Persistent myocardial blush; the contrast agent enters the microvasculature, but it does not normally pass to the venous phase: “persistent stain” is detected at the beginning of the next injection (≥30 s)</td>
</tr>
<tr>
<td>2</td>
<td>Delayed blush and washout of the myocardium: the myocardial stain is evident (maximum level or minimum decline in intensity) by the end of the injection (3 heart beats for washout)</td>
</tr>
<tr>
<td>3</td>
<td>Normal blush: entry and exit of the contrast agent from the microvasculature at normal speed (total or high washout of the dye within 3 heart beats)</td>
</tr>
<tr>
<td><strong>Microvascular flow: myocardial blush grades (MBG)</strong></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Absence of myocardial blush or “persistent stain,” indicative of the contrast exiting the extravascular space</td>
</tr>
<tr>
<td>1</td>
<td>Minimal myocardial blush</td>
</tr>
<tr>
<td>2</td>
<td>Moderate myocardial blush, of smaller intensity than in the reference area supplied by the non-culprit ipsilateral or contralateral artery</td>
</tr>
<tr>
<td>3</td>
<td>“Normal” myocardial blush, similar to the reference area</td>
</tr>
</tbody>
</table>
The analyzed assessment is performed by core laboratories with wide experience.\(^{62,63}\)

2. The filling time of the left anterior descending coronary artery (LAD) is higher than in other arteries, because this is normally the longest artery. Given that the filling of this artery can be simultaneously compared with the filling of the circumflex artery, the tendency to assign a TIMI grade 2 flow is much greater than with the right coronary artery (RCA).\(^{64}\)

3. The TIMI group itself has modified (without much acceptance) the grading system to distinguish up to 3 different subgroups in TIMI 2\(^{65}\) (Table 1). These changes include factors such as washout speed that will be later discussed.

4. Finally, we cannot discard the presence of factors that could significantly modify grading, such as the pressure and phase within the cardiac cycle at which the contrast injection is administered, the heart rate and blood pressure of the patient, the use of vasodilators, etc. The impact of these factors is discussed in the next section.

**Open Epicardial Artery: Quantification. Corrected TIMI Frame Count**

In the light of the potential limitations of the TIMI flow grading system, new evaluation systems have been developed that more deeply characterize flow and improve the reproducibility of results: the corrected TIMI frame count (cTFC) system developed by Gibson et al\(^{64}\) is the most widely validated. Basically, it quantifies the TIMI flow grade by measuring the time it takes the contrast agent to fill the entire length of the epicardial artery. In order to standardize the criteria, several distal bifurcations were defined to serve as “final landmarks”: the “whale’s tail” at the apex of the LAD, the longest total distance along which dye travels in the circumflex system and yet passes through the culprit lesion, and the first branch of the posterolateral artery in the right coronary artery (Figure 1). The difference in the number of frames between the last one and the first (where the contrast agent fills at least 70% of the arterial ostium and starts to move in an anterograde direction) constitutes the TIMI frame count.

Some of the methodological aspects of this system are outlined as follows:

1. As described,\(^{64}\) the length of the LAD is 1.7 times greater than the circumflex and the right coronary arteries. Thus, a correction factor was introduced in the TFC system when analyzing the LAD: the corrected TIMI frame count (cTFC) is the result of the absolute difference divided by the correction factor, 1.7.

2. All the values initially published as “frame counts” referred to the video format standard in the United States, NTSC: 30 frames per second. In order
to adapt these values to the European system (PAL), they have to be converted or else use a standard measuring unit: time in seconds. Table 2 shows the most relevant values and their equivalence.

3. The original definition of this parameter includes defining the cTFC value <100 when the coronary artery is totally occluded. This leads to a distribution of values that does not follow a normal distribution, which entails using nonparametric statistical tests to analyze the results.

4. Implementing this method in practice is more complex than simple subjective assessment of flow because it takes longer, which is a very significant restriction in the context of acute patients.

This parameter has been correlated with the onset of major events, such as early mortality after fibrinolysis,\textsuperscript{61,62,67} This relationship is kept even when the analysis is restricted to patients with TIMI 3 flow: the patients with cTFC values less than 14 frames (which was defined as “TIMI 4 flow”\textsuperscript{66,68}) presented a hospital mortality of 0%, compared to 2.7% in the group with cTFC between 14 and 40 frames (TIMI 3 flow) or to 6.4% in those with > 40 frames ($P = .003$).\textsuperscript{66} The relationship of cTFC to later prognosis has been demonstrated in other contexts, such as in primary angioplasty after infarction\textsuperscript{69-72} and in non-ST-segment elevation acute coronary syndrome (NSTEACS).\textsuperscript{73}

The correlation with independent methods of coronary functioning assessment (e.g. coronary flow reserve assessed by Doppler guidewire\textsuperscript{76,77} or fractional flow reserve [FFR]\textsuperscript{80}) has also been demonstrated. In complete contrast, some studies report no correlation between cTFC and coronary flow reserve parameters as measured by Doppler guidewire\textsuperscript{77,78} or even with early mortality.\textsuperscript{75} However, these studies assessed the flow in a limited number of patients after PCI and not at baseline. Thus, it is reasonable not to find a correlation between the baseline flow assessed by this method and the hyperemic flow analyzed via Doppler guidewire.

This method has obvious advantages over the qualitative assessment of epicardial flow:

1. Given the quantitative character of the parameter, high reproducibility has been demonstrated.\textsuperscript{10,11,81}

2. This is an easy method that does not require special equipment and can be performed immediately after capturing angiographic images.

3. The cut-off points shown in Table 2 allow us to classify unclear epicardial flows.

Nevertheless, the method presents certain limitations as it has been found that some factors can significantly change the values calculated:

1. Heart rate. An increase of 20 heart beats/min shortens the count by 5 frames.\textsuperscript{82}

2. Using nitrates increases the count by 6 frames.\textsuperscript{80}

3. Injecting during the protodiastolic period reduces the count by 3-6 frames.\textsuperscript{80}

4. When the LAD is the culprit artery of the infarction: in such cases the count is higher than in the other arteries by 8 frames, even after correcting for length and adjusting for other variables.\textsuperscript{80}

It has not been demonstrated whether the calculation is affected by patient-dependent factors (e.g. age, sex, body size, blood pressure, or cardiovascular risk factors\textsuperscript{76,80}) or by procedure-dependent factors (injection pressure\textsuperscript{11} or type of contrast agent\textsuperscript{81}).

Taking this method as a basis, another assessment system has been developed, not only for the epicardial blood flow, but also for microcirculation flow—the assessment of the coronary blood flow reserve by analyzing the relationship of cTFC at baseline and cTFC after the administration of intracoronary\textsuperscript{76,77} or intravenous\textsuperscript{81} adenosine. This parameter has been correlated with Doppler guidewire analysis,\textsuperscript{74,80} although other studies have not confirmed this.\textsuperscript{77}

**TABLE 2.** Values of the Corrected TIMI Frame Count (by Number of Frames)

<table>
<thead>
<tr>
<th>Recording Speed</th>
<th>Normal Values (Healthy Volunteers)</th>
<th>TIMI 3 Flow (After Infarction)</th>
<th>TIMI 4 Flow (After Infarction)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 frames/s</td>
<td>$&lt; 21$</td>
<td>$&lt; 40$</td>
<td>$&lt; 14$</td>
</tr>
<tr>
<td>25 frames/s</td>
<td>$&lt; 18$</td>
<td>$&lt; 33$</td>
<td>$&lt; 12$</td>
</tr>
<tr>
<td>12.5 frames/s</td>
<td>$&lt; 9$</td>
<td>$&lt; 17$</td>
<td>$&lt; 6$</td>
</tr>
<tr>
<td>Seconds</td>
<td>$&lt; 0.7$</td>
<td>$&lt; 1.3$</td>
<td>$&lt; 0.5$</td>
</tr>
</tbody>
</table>

**ASSESSMENT OF MYOCARDIAL PERFUSION AND MICROCIRCULATION**

**Open Microvasculature: Assessment.**

**Myocardial Blush**

Since the classic descriptions of reperfusion injury and no reflow events were presented,\textsuperscript{11} the attempts to assess the state of myocardial perfusion after an infarction have increased. The resolution of the ST-segment\textsuperscript{92} is the simplest and most reproducible analysis. Another method widely used is the MCE,\textsuperscript{90,91} which, apart from being a non-invasive method, can be quantified. In both cases, the results have been correlated with the appearance of subsequent events.\textsuperscript{92-94,96-100}

With the increasing implementation of PCI as the treatment of choice for AMI, the availability of an early angiography is quite frequent and this has permitted the development of the myocardial blush...
TABLE 3. Treatment of Suboptimal Myocardial Perfusion

<table>
<thead>
<tr>
<th>Drug/Method</th>
<th>Result</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verapamil</td>
<td>Positive</td>
<td>Small studies104,116</td>
</tr>
<tr>
<td>Nicorandil</td>
<td>Positive</td>
<td>Small studies111,112</td>
</tr>
<tr>
<td>Caripride (Na+/H+ pump inhibitor)</td>
<td>Negative</td>
<td>GUARDIAN Study117</td>
</tr>
<tr>
<td>Intracoronary adenosine</td>
<td>Positive (subgroup)</td>
<td>AMISTAD II Study124</td>
</tr>
<tr>
<td>Abciximab (glycoprotein IIb/IIIa inhibitors)</td>
<td>Positive</td>
<td>Several studies125,126,139,140</td>
</tr>
<tr>
<td>Pexelizumab (complement inhibitor)</td>
<td>Pending</td>
<td>APEX AMI Study131</td>
</tr>
<tr>
<td>Hu23F25 (antibody anti-CD18)</td>
<td>Negative</td>
<td>HALT-AMI Study132</td>
</tr>
<tr>
<td>Glatirer (G-23 overbind inhibitor)</td>
<td>Pending</td>
<td>EVOLVE Study133,134</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Non-conclusive</td>
<td>Preliminary studies14,108</td>
</tr>
<tr>
<td>Aqueous hyperoxgenation</td>
<td>Non-conclusive</td>
<td>Preliminary studies14,108</td>
</tr>
<tr>
<td>Thrombectomy devices</td>
<td>Positive</td>
<td>Small studies14,108,109</td>
</tr>
<tr>
<td>Distal protection devices</td>
<td>Negative</td>
<td>EMERALD Study135</td>
</tr>
</tbody>
</table>

The assessment of myocardial blush has its own limitations:

1. The qualitative character of this parameter makes it inherently subjective. Thus, intra- and inter-observer consistency is limited, as described by one of the groups with the greatest experience.22 In most studies, the analysis of MBG or TMPG is performed in central laboratories, and thus, the consistency with the assessments carried out by other observers might not be suitable.

2. Many of the studies carried out tend to group patients with MBG 2 and 3 or TMPG 2 and 3 into a single group with suitable perfusion. Given that it has been demonstrated that the prognosis of patients with TIMI 2 and TIMI 3 flow is not equivalent, this simplification of the system is most probably wrong.

3. Nevertheless, the fundamental limitation is not methodological, but refers to the unsolved challenge of treating suboptimal myocardial perfusion after coronary reperfusion. Table 3 sums up evidence published in this domain.

The correlation between the analysis of ST-segment resolution and myocardial blush is controversial because, although both have been related to clinical events, they do not always seem to match in every patient. What could be interpreted as a limitation tends to be assessed as another “anomalous” event, which are not uncommon in cardiology: the “electrical recovery” shown in the ECG is not always associated with integrity of the microvascular endothelium and recovery of perfusion, and vice versa. In fact, the 2 methods are complementary when the size of the infarction,14 or the angiography are analyzed. Their complementarity is also shown by the fact that the
There is ample literature available on the correlation between MCE and angiography. Although a perfect correlation is not always found, even though both methods, at least theoretically, analyze myocardial perfusion. Bearing in mind that this is a dynamic event (some days after the infarction, many patients that initially did not show suitable myocardial blush may show a much better grade), the discrepancies may be due to the behavior of the different contrast agent used—echocardiographic contrast agents (micobubbles) always remain in the intravascular space, whereas radiological contrast media (and paramagnetic contrast used in magnetic resonance) often present extravascular passage, subsequently returning to the bloodstream. Thus, some authors argue that angiography or magnetic resonance do not actually assess myocardial perfusion, but rather capillary patency, the state of the endothelium, and the edema and interstitial hemorrhage i.e. reperfusion injury.
Open Microvasculature: Quantification. Future Development

Myocardial perfusion assessed by angiography is analyzed by using several quantitative methods:

1. Methods based on digital subtraction angiography (DSA), widely used in vascular radiology, but little used in coronary angiography, may facilitate the quantification of the opacified area (in theory, this is “equivalent” to areas quantified in MCE), blush intensity (“MBG quantification”) or the speed at which the blush appears or disappears (“TMPG quantification”). For DSA to be more applicable, several studies are working on the development of techniques, such as moving mask, to attempt to neutralize the movements inherent to the heart.

2. A quantification system, based on cTFC has been suggested. This quantifies the number of frames between the entrance of the contrast agent into the myocardium and the peak blush intensity: the TIMI myocardial frame count. This count is significantly greater in patients with AMI with ST-segment elevation than in patients with NSTEACS.

3. Our group has developed a quantification system known as the Coronary Clearance Frame Count (CCFC) with good correlation with TMPG grades. Defined as “the inverse of cTFC,” it counts the difference in frames between the moment in which the...
contrast disappears from the arterial ostium and when it begins to disappear from the distal bifurcation described in the cTFC system. Although its potential clinical relevance has not been established yet, it shows correlation with myocardial perfusion TMPG grade 2 or 3, creating a cut-off point (45 images) that makes it possible to differentiate the better perfusion grades.

cTFC Analysis and Myocardial Blush. Practical Considerations

Both the quantitative analysis of epicardial blood flow (cTFC) and microvascuature flow can be carried out online with current digital equipment, or offline with software for image review. Nevertheless, if the imaging conditions are not optimal, the interpretation and later analysis may be biased. Thus, some standard recommendations are made:

1. Imaging field: 23 cm. Not magnifying the image enables recording the whole length of the artery without the need for panning. This is particularly important for the correct analysis of myocardial blush, especially when DSA is used. The quality of current DSA images (fixed mask) is also highly dependant on maintaining apnea during the recording.
2. Imaging speed: ideally, 25 frames/s. Nevertheless, cTFC can be calculated at any recording speed, and subsequently it can be expressed in seconds or adjusted to the recommended speed.
3. Recording time: up to the appearance of contrast in the venous phase. This is very relevant for the TMPG analysis system. In this case, it is also particularly important to leave at least 30 s between one injection and the following one, and not to record immediately after contrast tests (it may incorrectly assign TMPG 1 values).
4. Selective projections:
   a) Analysis of cTFC. Recording images in PA or RAO projection (0°-30°) is recommended with caudal angulation (20°-30°) for the left coronary artery and in LAO projection (45°-60°) for the right coronary artery.
   b) Blush analysis: the recommended projections differ from the previous ones, especially in the left coronary artery, where perfusion territories may be seen as overlapping. Thus, LAO projection (45°-60°) is recommended with cranial angulation (20°-30°), which makes it possible to see a donut-like image, or a left lateral projection (90°) in the case of the left coronary artery; for the right coronary artery, an LAO projection is recommended (45°-60°) with without cranial angulation or RAO (30°).

From a practical point of view, in our center we systematically analyze myocardial perfusion data from angiographies (according to both the TMPG and the MBG system) in all cases of angioplasty within the context of AMI and in other cases of intervention with no reflow events or slow final blood flow, reserving cTFC and CCFC for cases with no data to classify epicardial blood flow or perfusion. In all these cases, the information obtained is always complemented by electrocardiographic analysis of ST-segment resolution.

CONCLUSIONS

Coronary angiography offers relevant but simple and easy to interpret information, not only on the state of the epicardial coronary circulation (TIMI flow in the epicardial artery and its quantification, TIMI frame count), but also on the state of microvascular circulation (myocardial blush grades: TIMI myocardial perfusion and myocardial blush grades). These data allow us to reliably assess the patient’s prognosis. The development of a quantitative variant of these techniques could improve their predictive power.

REFERENCES


cutaneous coronary intervention: incidence, predictors, and out-
41. Laster SB, O’Keefe JH Jr, Gibbons RJ. Incidence and impor-
tance of thrombosis in myocardial infarction grade 3 flow fol-
after primary percutaneous transluminal coronary angio-
44. Canon CI. Importance of TIMI 3 flow. Circulation. 2001;104:
64-6.
45. Trial of abciximab with and without low-dose rt-PA for acu-
101:2788-94.
46. Gibson CM, Jennings LG, Murphy SA, Lorenz DP, Giugliano RP, Hunnington RA, et al. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among pa-
tients with ST-segment-elevation myocardial infarction: an IN-
TEGRITI (Integrilin and Tenecteplase in Acute Myocardial In-
47. Antman EM, Louwerenburg JW, Baars HF, Wexrop JC, Ha-
49. Antman EM, Giugliano RP, Cousseneti M, Kleinman NS, et al. Abciximab facilitates the rate and extent of thrombolytic: results of the thrombolysis in myocar-
dial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Cir-
50. Antman EM, De Lemos JA, Giugliano RP, McCa-
bere CH, Cousseneti P, et al. Combination reperfusion therapy with abciximab and reduced dose rt-PA: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 In-
51. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Gia-
luiaio NP, Murphy SA, et al. Abciximab improves both epicardial and microcirculatory perfusion in ST-elevation myocardial in-
101:2394-3.
52. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, Sti-
fur G, et al. Procedural, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: inh-
hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investiga-
53. Giugliano RP, Cox DA, Stone GW, Garcia E, Mattos LA, Giambi-
netra A, et al. Coronary angioplasty with or without stent im-
plantation for acute myocardial infarction. Stent Primary An-
cardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2001;42:1395-
402.
ing percutaneous coronary intervention for acute myocardial in-
58. Tsuchi K, Kanaya T, Tsu T, Abe S, Sugama H, Hosoe T, et al. Comparison of the effects of a distal embolic protection device and an aspiration catheter during percutaneous coronary inter-
1063-72.
137:1179-84.
64. Ellis SG, Topol ES, George RS, Kerrekes DJ, Dehovoy D, Sapi-
son KN, et al. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Cir-
65. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCa-
bec P, et al. Relationship between TIMI frame count and clini-
67. Edip ME, Glaum E, Teisman PS, Phillips PS, Brown DL. Diff-
ferences in TIMI frame count following successful reperfu-
sion with stenting or percutaneous transluminal coronary angio-
plasty for acute myocardial infarction. Am J Cardiol. 1999;
83:1326-9.
68. Hamada S, Nishino T, Nakamura S, Sugito T, Kamihita H, Mi-
oshii H, et al. TIMI frame count immediately after primary co-
69. Vrachnos AD, Alpent MA, Georpolias VP, Nikas DJ, Petropou-
lou EN, Lairosz GI, et al. Comparative efficacy of primary an-
gioplasty with stent implantation and thrombolysis in restoring
basal coronary artery flow in acute ST segment elevation myo-
cardial infarction: quantitative assessment using the corrected
71. Bickel C, Rippecht B, Mannningting A, Welk I, Blanka-
berg S, Krummenauer F, et al. The superiority of TIMI frame count
in detecting coronary flow changes after primary stenting com-
pared to TIMI Flow Classification. J Cardiovasc Interv. 2002;14:
464-73.
72. Capuzziolo C, Pisani F, de Luca G, Coppa A, Mazzarotto P, Le-
visco D, et al. Direct coronary stenting: effect on coronary
blood flow, immediate and late clinical results. Catheter Cardi-
73. Gibson CM, Dotani MI, Murphy SA, Marble SJ, Dausterman
KW, Michaels AD, et al. Correlates of coronary blood flow be-
fore and after percutaneous coronary intervention and their rela-
tionship to angiographic and clinical outcomes in the RESTORE
trial. Randomized Efficacy Study of Tirofiban for Outcomes and
74. Manginas A, Gatzoulis P, Chaukidis C, Voudas V, Perdiles G,
Cokkinos DV. Estimation of coronary flow reserve using the
Thrombolysis In Myocardial Infarction (TIMI) frame count met-
75. Baxin C, Drntas AE, Gournik KN, Higano ST, Holmes DR Jr,
Lerman A. Relation of Thrombolysis in Myocardial Infarction (TIMI)
frame count to coronary flow parameters. Am J Cardiol.
76. Umman B, Nocanc Y, Sezer M, Umman S, Yilmaz E, Ofcar H,
et al. The relationship between corrected TIMI frame count and
myocardial fractional flow reserve. J Invasive Cardiol. 2002;14:
125-6.
77. Chugh SK, Koppel J, Scott M, Shewchuk L, Goodhart D, Bonan
T, et al. Relation between the TIMI frame count and the degree
of microvascular coronary injury and the degree of myocardial
78. Okura Y, Hisao Y, Takahashi T, Yamaguchi K, Ogura R, Ogata
T, et al. Relation between the TIMI frame count and the degree of
microvascular injury after primary angioplasty in patients with
acute anterior myocardial infarction. Heart. 2005;
91:64-7.
79. Bhatt DL, Ellis SG, Italic TB, Crowe T, Balaz M, Dohobyo D,
et al. Corrected TIMI frame count does not predict 30-day ad-
verse outcomes after reperfusion therapy for acute myocardial
80. Abaci A, Oguzhan A, Eryol NK, Ergin A. Effect of potential
confounding factors on the thrombolysis in myocardial infarc-
tion (TIMI) trial frame count and its reproducibility. Circulation.
1999;100:2219-23.
81. Gibson CM, Murphy S, Menon IB, Sequeira BF, Greene R,
van de Weert F, et al. Determinants of coronary blood flow after
thrombolytic administration. TIMI Study Group. Thrombolytic in
82. Faile BA, Guzzo JA, Tate DA, Nichols TC, Smith SC, Dehmer
GJ. Effect of sex, hemodynamics, body size, and other clinical
variables on the corrected thrombolysis in myocardial infarction
count used as an assessment of coronary blood flow. Am
83. Dodge JT Jr, Rizzo M, Nyckel M, Altman J, Holburn K, Bren-
am M, et al. Impact of injection rate on the Thrombolysis in
Myocardial Infarction (TIMI) trial frame count. Am J Cardiol.
84. Gibson CM, Kirtane AJ, Murphy SA, Marble SJ, de Lemos JA,
Antman EM, et al. Impact of clinical outcomes following thromboly-
thetic administration in acute myocardial infarction. Catheter Car-
85. Gibson CM, Cohen DJ, Cohen EA, Liu HK, Murphy SA, Mar-
ble SJ, et al. Effect of epitrochoid on coronary flow reserve fol-
lowing coronary stent implantation (an ESPRIT substudy). En-
hanced Suppression of the Platelet IIb/IIIa Receptor with Inte-
86. Stoel MG, Girola F, Visser CA. Frame count rate. Circula-
tion. 2003;107:3034-5.
87. Kloner RA, Rude RE, Carlson N, Muroko PR, DeBolt LW,
Braunwald E. Ultrastructural evidence of microvascular in-
myocardial and myocardial cell injury after coronary artery occlusion: which comes first? Circulation. 1992;86:
778-82.
88. Ito H, Iwakura K, Ot H, Masuyama T, Hori M, Higashino Y,
et al. Temporal changes in myocardial perfusion patterns in pa-
tients with reperfused anterior wall myocardial infarction: their
89. Ito H, Masuyama A, Iwakura K, Takachi S, Masuyama T, Hori
M, et al. Clinical implications of the ‘no reflow’ phenomenon. A
producer of complications and left ventricular remodeling in
reperfused anterior wall myocardial infarction. Circulation.
90. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takachi
S, et al. Myocardial perfusion patterns related to thrombolysis in
myocardial infarction perfusion grades after coronary angio-
plasty in patients with acute anterior wall myocardial infarction.
91. Assmann T, Tansche K, Ochiasy K, Yoshimori H, Nakamura K,
Murakuma Y, et al. Relationship between progresive microvas-
cular damage and intramyocardial hemorrhage in patients with
reperfused anterior myocardial infarction: myocardial contrast
92. Ito H, Iwakura K. Assessing the relation between coronary re-
93. Ruperto M, Caracozza G, Kaul S, Powers ER, Sarembock IJ,
Gimple LW. Microvascular integrity indicates myocardial via-
bility in patients with recent myocardial infarction. New insights
into myocardial contrast echocardiography. Circulation.
94. Greaves K, Dixon SR, Fejka M, O’Neill WR, Redwood SR,
Murber MS, et al. Myocardial contrast echocardiography is su-
perior to other known modalities for assessing myocardial re-
perfusion after acute reperfusion therapy for acute myocardial
95. Boki V, Sanchez J, Lopez-Lorena MP, Llacau A, Pellcier M,
Losa A, et al. Estudio de perfusion en pacientes postinfarto me-
diante ecografia mio-cardica con inyeccion de contraste intra-
vascular. Implicaciones y relacion con la angiografia y la
96. Bolognesi L, Ducati K, Angioli P, Falsini G, Liistro F, Baldassa-
re S, et al. Elevations in troponin I after percutaneous coronary
interventions compared to TIMI Flow Classification. J Invasive
97. Greaves K, Scherm A. Coronary and myocardial angio-
graphy: angiographic assessment of both epicardial and myocar-
98. Henriques JP, Zijlstra F, van’t Hof AW, de Bier MJ, Dambrink
JH, Gosselink M, et al. Angiographic assessment of reperfu-
sion in acute myocardial infarction by myocardial blush grade. Cir-
99. Gibson CM, Schomig A. Coronary and myocardial angio-
graphy: angiographic assessment of both epicardial and myocar-
100. Henriques JP, Zijlstra F, van’t Hof AW, de Bier MJ, Dambrink
JH, Gosselink M, et al. Angiographic assessment of reperfu-
sion in acute myocardial infarction by myocardial blush grade. Cir-
JH, Gosselink M, et al. Angiographic assessment of reperfu-
sion in acute myocardial infarction by myocardial blush grade. Cir-
102. Henriques JP, Zijlstra F, van’t Hof AW, de Bier MJ, Dambrink
JH, Gosselink M, et al. Angiographic assessment of reperfu-
sion in acute myocardial infarction by myocardial blush grade. Cir-


